Pacific Biosciences of California, Inc. Cost of Revenue
Pacific Biosciences of California, Inc. (PACB) reported Cost of Revenue of $26.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2026-08-06
- Pacific Biosciences of California, Inc. cost of revenue for the quarter ending 2026-06-30 was $26.37M, a 5.13% increase year-over-year.
- Pacific Biosciences of California, Inc. cost of revenue for the quarter ending 2026-03-31 was $24.34M, a 36.83% decline year-over-year.
- Pacific Biosciences of California, Inc. cost of revenue for the quarter ending 2025-12-31 was $28.08M, a 3.73% decline year-over-year.
- Pacific Biosciences of California, Inc. cost of revenue for the quarter ending 2025-09-30 was $22.54M, a 24.77% decline year-over-year.
- Pacific Biosciences of California, Inc. cost of revenue for fiscal 2025 was $114.22M, a 2.15% decline from fiscal 2024.
- Pacific Biosciences of California, Inc. cost of revenue for fiscal 2024 was $116.73M, a 20.99% decline from fiscal 2023.
- Pacific Biosciences of California, Inc. cost of revenue for fiscal 2023 was $147.74M, a 86.38% increase from fiscal 2022.
- Pacific Biosciences of California, Inc. cost of revenue for fiscal 2022 was $79.27M, a 10.63% increase from fiscal 2021.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.37M 10-Q · filed 2026-08-06 | $50.71M 10-Q · filed 2026-08-06 | $78.78M derived: sum of 3 quarters · filed 2026-08-06 | $101.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $24.34M 10-Q · filed 2026-05-08 | $52.42M derived: sum of 2 quarters · filed 2026-05-08 | $74.96M derived: sum of 3 quarters · filed 2026-05-08 | $100.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $28.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $50.62M derived: sum of 2 quarters · filed 2026-02-25 | $75.70M derived: sum of 3 quarters · filed 2026-08-06 | $114.22M 10-K · filed 2026-02-25 |
| 2025-09-30 | $22.54M 10-Q · filed 2025-11-06 | $47.62M derived: sum of 2 quarters · filed 2026-08-06 | $86.15M 10-Q · filed 2025-11-06 | $115.31M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $25.08M 10-Q · filed 2026-08-06 | $63.61M 10-Q · filed 2026-08-06 | $92.77M derived: sum of 3 quarters · filed 2026-08-06 | $122.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $38.52M 10-Q · filed 2026-05-08 | $67.69M derived: sum of 2 quarters · filed 2026-05-08 | $97.65M derived: sum of 3 quarters · filed 2026-05-08 | $127.73M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $29.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $59.13M derived: sum of 2 quarters · filed 2026-02-25 | $89.20M derived: sum of 3 quarters · filed 2026-02-25 | $116.73M 10-K · filed 2026-02-25 |
| 2024-09-30 | $29.96M 10-Q · filed 2025-11-06 | $60.04M derived: sum of 2 quarters · filed 2025-11-06 | $87.57M 10-Q · filed 2025-11-06 | $136.35M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $30.07M 10-Q · filed 2025-08-07 | $57.60M 10-Q · filed 2025-08-07 | $106.39M derived: sum of 3 quarters · filed 2026-02-25 | $144.18M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $27.53M 10-Q · filed 2025-05-12 | $76.31M derived: sum of 2 quarters · filed 2026-02-25 | $114.10M derived: sum of 3 quarters · filed 2026-02-25 | $146.13M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $48.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $86.58M derived: sum of 2 quarters · filed 2026-02-25 | $118.60M derived: sum of 3 quarters · filed 2026-02-25 | $147.74M 10-K · filed 2026-02-25 |
| 2023-09-30 | $37.79M 10-Q · filed 2024-11-12 | $69.82M derived: sum of 2 quarters · filed 2024-11-12 | $98.95M 10-Q · filed 2024-11-12 | $121.17M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $32.03M 10-Q · filed 2024-08-09 | $61.17M 10-Q · filed 2024-08-09 | $83.38M derived: sum of 3 quarters · filed 2025-03-17 | $102.14M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $29.14M 10-Q · filed 2024-05-09 | $51.35M derived: sum of 2 quarters · filed 2025-03-17 | $70.12M derived: sum of 3 quarters · filed 2025-03-17 | $89.39M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $22.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $40.98M derived: sum of 2 quarters · filed 2025-03-17 | $60.25M derived: sum of 3 quarters · filed 2025-03-17 | $79.27M 10-K · filed 2025-03-17 |
| 2022-09-30 | $18.76M 10-Q · filed 2023-11-03 | $38.04M derived: sum of 2 quarters · filed 2023-11-03 | $57.06M 10-Q · filed 2023-11-03 | $76.31M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $19.27M 10-Q · filed 2023-08-04 | $38.29M 10-Q · filed 2023-08-04 | $57.55M derived: sum of 3 quarters · filed 2024-02-28 | $77.07M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $19.02M 10-Q · filed 2023-05-04 | $38.27M derived: sum of 2 quarters · filed 2024-02-28 | $57.79M derived: sum of 3 quarters · filed 2024-02-28 | $74.65M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $19.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $38.78M derived: sum of 2 quarters · filed 2024-02-28 | $55.63M derived: sum of 3 quarters · filed 2024-02-28 | $71.65M 10-K · filed 2024-02-28 |
| 2021-09-30 | $19.52M 10-Q · filed 2022-11-08 | $36.38M derived: sum of 2 quarters · filed 2022-11-08 | $52.40M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $16.86M 10-Q · filed 2022-08-08 | $32.88M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $16.02M 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | $46.33M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $56.31M 10-K · filed 2022-02-28 | |||
| 2018-03-31 | $12.07M 10-Q · filed 2018-05-02 | $27.51M derived: sum of 2 quarters · filed 2018-05-02 | $42.83M derived: sum of 3 quarters · filed 2018-05-02 | $54.90M derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-12-31 | $15.44M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $30.76M derived: sum of 2 quarters · filed 2018-02-26 | $42.83M derived: sum of 3 quarters · filed 2018-02-26 | $58.81M 10-K · filed 2018-02-26 |
| 2017-09-30 | $15.32M 10-Q · filed 2017-11-02 | $27.39M derived: sum of 2 quarters · filed 2017-11-02 | $43.37M 10-Q · filed 2017-11-02 | $57.72M derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-06-30 | $12.07M 10-Q · filed 2017-08-02 | $28.05M 10-Q · filed 2017-08-02 | $42.40M derived: sum of 3 quarters · filed 2018-05-02 | $54.88M derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-03-31 | $15.98M 10-Q · filed 2018-05-02 | $30.33M derived: sum of 2 quarters · filed 2018-05-02 | $42.81M derived: sum of 3 quarters · filed 2018-05-02 | $52.91M derived: sum of 4 quarters · filed 2018-05-02 |
| 2016-12-31 | $14.35M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $26.83M derived: sum of 2 quarters · filed 2018-02-26 | $36.93M derived: sum of 3 quarters · filed 2018-02-26 | $46.55M 10-K · filed 2018-02-26 |
| 2016-09-30 | $12.48M 10-Q · filed 2017-11-02 | $22.58M derived: sum of 2 quarters · filed 2017-11-02 | $32.21M 10-Q · filed 2017-11-02 | $42.02M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-06-30 | $10.10M 10-Q · filed 2017-08-02 | $19.73M 10-Q · filed 2017-08-02 | $29.54M derived: sum of 3 quarters · filed 2018-02-26 | $36.91M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-03-31 | $9.62M 10-Q · filed 2017-05-05 | $19.44M derived: sum of 2 quarters · filed 2018-02-26 | $26.80M derived: sum of 3 quarters · filed 2018-02-26 | $37.24M derived: sum of 4 quarters · filed 2018-02-26 |
| 2015-12-31 | $9.81M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $17.18M derived: sum of 2 quarters · filed 2018-02-26 | $27.61M derived: sum of 3 quarters · filed 2018-02-26 | $39.33M 10-K · filed 2018-02-26 |
| 2015-09-30 | $7.37M 10-Q · filed 2016-11-04 | $17.80M derived: sum of 2 quarters · filed 2016-11-04 | $29.52M 10-Q · filed 2016-11-04 | $41.98M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-06-30 | $10.43M 10-Q · filed 2016-08-04 | $22.15M 10-Q · filed 2016-08-04 | $34.62M derived: sum of 3 quarters · filed 2017-03-06 | $42.08M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-03-31 | $11.72M 10-Q · filed 2016-05-05 | $24.18M derived: sum of 2 quarters · filed 2017-03-06 | $31.64M derived: sum of 3 quarters · filed 2017-03-06 | $39.94M derived: sum of 4 quarters · filed 2017-03-06 |
| 2014-12-31 | $12.47M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $19.93M derived: sum of 2 quarters · filed 2017-03-06 | $28.23M derived: sum of 3 quarters · filed 2017-03-06 | $37.19M 10-K · filed 2017-03-06 |
| 2014-09-30 | $7.46M 10-Q · filed 2015-11-05 | $15.76M derived: sum of 2 quarters · filed 2015-11-05 | $24.73M 10-Q · filed 2015-11-05 | $30.67M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | $8.30M 10-Q · filed 2015-08-05 | $17.27M 10-Q · filed 2015-08-05 | $23.21M derived: sum of 3 quarters · filed 2016-03-11 | $29.39M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | $8.97M 10-Q · filed 2015-05-05 | $14.91M derived: sum of 2 quarters · filed 2016-03-11 | $21.09M derived: sum of 3 quarters · filed 2016-03-11 | $26.08M derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | $5.94M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $12.12M derived: sum of 2 quarters · filed 2016-03-11 | $17.11M derived: sum of 3 quarters · filed 2016-03-11 | $21.76M 10-K · filed 2016-03-11 |
| 2013-09-30 | $6.18M 10-Q · filed 2014-11-05 | $11.17M derived: sum of 2 quarters · filed 2014-11-05 | $15.82M 10-Q · filed 2014-11-05 | $21.07M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-06-30 | $4.99M 10-Q · filed 2014-08-05 | $9.64M 10-Q · filed 2014-08-05 | $14.89M derived: sum of 3 quarters · filed 2015-03-12 | $17.47M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-03-31 | $4.65M 10-Q · filed 2014-05-08 | $9.90M derived: sum of 2 quarters · filed 2015-03-12 | $12.48M derived: sum of 3 quarters · filed 2015-03-12 | $19.50M derived: sum of 4 quarters · filed 2015-03-12 |
| 2012-12-31 | $5.25M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $7.84M derived: sum of 2 quarters · filed 2015-03-12 | $14.85M derived: sum of 3 quarters · filed 2015-03-12 | $25.04M 10-K · filed 2015-03-12 |
| 2012-09-30 | $2.59M 10-Q · filed 2013-11-12 | $9.60M derived: sum of 2 quarters · filed 2013-11-12 | $19.79M 10-Q · filed 2013-11-12 | $30.70M derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-06-30 | $7.02M 10-Q · filed 2013-08-09 | $17.21M 10-Q · filed 2013-08-09 | $28.11M derived: sum of 3 quarters · filed 2014-03-14 | $35.30M derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-03-31 | $10.19M 10-Q · filed 2013-05-10 | $21.10M derived: sum of 2 quarters · filed 2014-03-14 | $28.29M derived: sum of 3 quarters · filed 2014-03-14 | $31.02M derived: sum of 4 quarters · filed 2014-03-14 |
| 2011-12-31 | $10.91M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $18.10M derived: sum of 2 quarters · filed 2014-03-14 | $20.83M derived: sum of 3 quarters · filed 2014-03-14 | $20.83M 10-K · filed 2014-03-14 |
| 2011-09-30 | $7.19M 10-Q · filed 2012-11-01 | $9.92M derived: sum of 2 quarters · filed 2012-11-01 | $9.92M 10-Q · filed 2012-11-01 | |
| 2011-06-30 | $2.73M 10-Q · filed 2012-08-07 | $2.73M 10-Q · filed 2012-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |